Thai health ministry officials have confirmed that two cases of the bird flu virus, HN51, have been reported in separate hospitals in Thailand. the Health Ministry officials confirmed tests on patients in the Suphanburi and Kanchanaburi provinces had been carried out and returned positive with the HN51 virus. the news arrived a few days after Japan suspended chicken imports from Thailand, which has a huge and lucrative poultry industry. Top economic and health ministers had held an urgent meeting to map out strategies to cope with the economic and health impact should the laboratory results prove that bird flu has leaped to humans, as it has in Vietnam. If your intending to travel to Thailand soon then the one of the better ways to avoid and combat the threat of the bird flu virus is to take shikimic acid, an extract of star anise. This extract is currently being used extensively in a well known anti viral medication but with great demand and lack of ingredient, levels are currently running very low. Luckily there is a product available that contains a concentrated star anise and is one way to help help oneself one from this virus. Bioflu has been developed with the aim of combating viruses. Bioflu contains anti-viral properties in the form of a synergistic blend of star anise, Siberian ginseng and black elderberry extracts that work together to strengthen the immune system and improve your recovery times. Double blind university medical school human trials have shown the ingredients in Bioflu to be effective in greatly reducing the severity and duration of the symptoms of influenza viruses. and to make sure that you are properly covered for your travels, Biotivia are offering two bottles of Bioflu for the price of one all through May 2011. to qualify for the offer, just visit the site and enter the voucher code “FREEFLU” at the check out to read more about Bioflu please visit biotivia.co.uk/company/news/travelling-to-the-far… About Biotivia LLC Biotivia was established in 1992 in Vienna, Austria as a supplier of natural raw materials and botanicals to the supplement and functional food industries and to researchers and scientific institutions worldwide. the company evolved into one of the world’s leading developers and suppliers of potent nutritional supplements and skin care therapies, with most of their products centered around the use of concentrated resveratrol and complementary botanical extracts. Biotivia presently has US offices in New York, Los Angeles, Kansas City and international offices in the UK, Spain, Austria, Denmark, Italy, Germany, Singapore, Xi’an, China and Mumbai, India. Beyond its strong consumer base, the company currently supplies researchers, physicians and scientists at Harvard, Stanford, Yale, Georgetown, the Albert Einstein Medical Center, University of Texas, M.D. Anderson Cancer Center and the University of California. Transmax and Bioforte in particular are being explored by several major universities as a possible treatment for a variety of conditions that seriously impair the health and well being of millions of people around the world. Biotivia recently signed an agreement to supply Transmax to the University of Ferrara for use in three human clinical trials in Italy and Egypt on its possible use by Thalassemia sufferers. Biotivia’s resveratrol products, Transmax and Bioforte, have been independently assessed by Consumer Labs, the leading American quality watchdog, and were deemed both ‘most potent’ and ‘best value’. Most of Biotivia’s other supplements have been certified Vegan by the American Vegetarian Association. neither Bioflu nor any Biotivia product has been shown to prevent flu or viruses. Bioflu is not intended to diagnose, prevent, treat or cure any disease. the statements herein have not been reviewed or approved by the US FDA. all Biotivia supplements are manufactured in state of the art FDA inspected pharmaceutical facilities in accordance with CGMP USP standards. Contact information: Leo Day

This press release was distributed via Response Source, a service from Daryl Willcox Publishing, on behalf of Biotivia Bioceuticals LLC. For more information visit dwpub.com/pressreleasewires